Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience.
OBJECTIVE
The aim of this work was to retrospectively analyze patients with Philadelphia-negative myeloproliferative neoplasms through evaluation of frequency and characteristics of second malignancies (other than acute leukaemia and myelodysplastic syndrome).


METHODS
Records of 172 patients were reviewed; an analysis was performed on data from 66 patients treated with hydroxyurea, 105 patients treated with other cytoreductive therapy, and 25 patients without treatment.


RESULTS
A higher occurrence of second malignancies was found in the group treated with hydroxyurea (7.6%; other cytoreduction: 1.2%; without therapy: 0). After a median follow-up of 89 months in the hydroxyurea group, 13 patients developed second cancer during hydroxyurea therapy, located on the skin (68.75%) and other sites (31.25%).


CONCLUSIONS
The incidence of second malignancies during hydroxyurea therapy in our cohort patient was significantly higher than the incidence of malignancies in the Czech population of corresponding age.
Department of Haematology, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic. jkissova@fnbrno.cz.
Jarmila
J
Kissova
Petra
P
Ovesna
Miroslav
M
Penka
Alena
A
Bulikova
Igor
I
Kiss
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015994:Incidence; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000453:epidemiology*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D006918:Hydroxyurea
Second malignancies; hydroxyurea; myeloproliferative neoplasm; skin cancer